NCT03587038 2025-12-10OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed GlioblastomaUniversity of OklahomaPhase 1 Active not recruiting27 enrolled
NCT05561374 2024-11-29Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade GliomaOblato, Inc.Phase 1 Active not recruiting16 enrolled